CORPORATE INFO
FOR INVESTORS
OUR PRODUCTS
BUSINESS DEVELOPMENT
CONTACT US
HOME
Menu
Financial Statements
Financial Reports
Securities Filing
Investor Resources
Fact Sheet
Presentations
Analyst Coverage
Calendar of Events
FAQ
Shareholder
Services
Investor Kit
Investor Information
News
Press Releases
Corporate News
Awards
PRESS RELEASES
COMMUNIQUÉS DE PRESSE (Français)
2013
|
2012
|
2011
|
2010
|
2009
|
2008
|
2007
|
2006
|
2005
|
2004
|
2003
|
2002
|
2001
|
2000
|
1999
|
1998
|
1997
|
November 11, 2009
PALADIN REPORTS RECORD THIRD QUARTER 2009 FINANCIAL RESULTS
(Also in
PDF
format)
November 4, 2009
NOTICE OF PALADIN LABS' 2009 THIRD QUARTER RESULTS CONFERENCE CALL
(Also in
PDF
format)
October 23, 2009
PALADIN LABS INC. RECEIVES $100,000 GRAND CHALLENGES EXPLORATIONS GRANT FOR INNOVATIVE GLOBAL HEALTH RESEARCH FROM GATES FOUNDATION
(Also in
PDF
format)
October 15, 2009
PALADIN LABS AND PFIZER AMEND CANADIAN ESTRING(R) AGREEMENT
(Also in
PDF
format)
September 30, 2009
PALADIN TO PRESENT AT BIOCONTACT CONFERENCE IN QUEBEC CITY
(Also in
PDF
format)
September 30, 2009
PALADIN LABS INC. ANNOUNCES SALE OF ANTIBODY PLATFORM TO QUEST PHARMATECH
(Also in
PDF
format)
September 24, 2009
HEALTH CANADA APPROVES GLUCAGEN(R) FOR TREATMENT OF SEVERE HYPOGLYCEMIA IN DIABETES PATIENTS
(Also in
PDF
format)
September 17, 2009
PALADIN TO PRESENT AT THE UBS GLOBAL LIFE SCIENCES CONFERENCE IN NEW YORK CITY
(Also in
PDF
format)
August 13, 2009
PALADIN LABS INC. ANNOUNCES SALE OF T-ACT PLATFORM TO IMBIOTECHNOLOGIES
(Also in
PDF
format)
August 11, 2009
PALADIN REPORTS 2009 SECOND QUARTER FINANCIAL RESULTS
(Also in
PDF
format)
August 4, 2009
NOTICE OF PALADIN LABS' 2009 SECOND QUARTER RESULTS CONFERENCE CALL
(Also in
PDF
format)
July 16, 2009
PALADIN LABS INC. ANNOUNCES RESEARCH AND DEVELOPMENT CONTRIBUTION FROM THE NATIONAL RESEARCH COUNCIL OF CANADA INDUSTRIAL RESEARCH ASSISTANCE PROGRAM FOR ITS CHIMIGEN(R) PLATFORM
(Also in
PDF
format)
June 29, 2009
PALADIN ACQUIRES PRODUCTS FROM WYETH
(Also in
PDF
format)
June 18, 2009
PALADIN LABS ANNOUNCES THE CLOSING OF ITS PARTNERSHIP FOR THE COMMERCIALIZATION OF VOCLOSPORIN
(Also in
PDF
format)
June 18, 2009
PALADIN LABS INC. SIGNS EXCLUSIVE AGREEMENT WITH SYLPHAR N.V.
(Also in
PDF
format)
June 17, 2009
PALADIN LABS ANNOUNCES CANADIAN LAUNCH OF TWINJECT(R) TWINPACK(TM) FOR ANAPHYLAXIS
(Also in
PDF
format)
June 11, 2009
PALADIN LABS ANNOUNCES GELICIOUS!(TM) AND GELMEG3(TM) LAUNCH
(Also in
PDF
format)
June 11, 2009
PALADIN ANNOUNCES CLOSING OF $58.7 MILLION BOUGHT DEAL FINANCING AND EXERCISE OF OVER-ALLOTMENT OPTION
(Also in
PDF
format)
May 21, 2009
PALADIN ENTERS INTO AGREEMENT FOR A $51 MILLION BOUGHT DEAL OF COMMON SHARES
(Also in
PDF
format)
May 7, 2009
PALADIN LABS AND ISOTECHNIKA INC. FORM PARTNERSHIP FOR COMMERCIALIZATION OF VOCLOSPORIN
(Also in
PDF
format)
May 7, 2009
PALADIN REPORTS 2009 FIRST QUARTER FINANCIAL RESULTS
(Also in
PDF
format)
April 30, 2009
NOTICE OF PALADIN LABS' FIRST QUARTER RESULTS CONFERENCE CALL
(Also in
PDF
format)
April 22, 2009
PALADIN TO PRESENT AT BIOFINANCE 2009 IN TORONTO
(Also in
PDF
format)
March 9, 2009
PALADIN FILES NEW DRUG SUBMISSION FOR TRELSTAR(R) 6 MONTH
(Also in
PDF
format)
February 27, 2009
PALADIN ANNOUNCES NORMAL COURSE ISSUER BID AND AUTOMATIC SHARE PURCHASE PLAN
(Also in
PDF
format)
February 26, 2009
PALADIN REPORTS RECORD 2008 FOURTH QUARTER AND YEAR END RESULTS
(Also in
PDF
format)
February 19, 2009
NOTICE OF PALADIN LABS' FOURTH QUARTER RESULTS CONFERENCE CALL
(Also in
PDF
format)
February 10, 2009
PALADIN TO PRESENT AT THE ROTH CAPITAL PARTNERS 21ST ANNUAL OC GROWTH STOCK CONFERENCE
(Also in
PDF
format)
January 14, 2009
MISSION PHARMACAL AND PALADIN COMPLETE AGREEMENT FOR UROCIT-K(R) FOR THE TREATMENT OF KIDNEY STONES
(Also in
PDF
format)
HOME
|
SITE MAP
|
LEGAL DISCLAIMER
